1. Home
  2. DHIL vs LCTX Comparison

DHIL vs LCTX Comparison

Compare DHIL & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Diamond Hill Investment Group Inc.

DHIL

Diamond Hill Investment Group Inc.

BUY

Current Price

$174.96

Market Cap

463.8M

Sector

Finance

ML Signal

BUY

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.66

Market Cap

391.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DHIL
LCTX
Founded
1990
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
463.8M
391.1M
IPO Year
1996
1996

Fundamental Metrics

Financial Performance
Metric
DHIL
LCTX
Price
$174.96
$1.66
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$5.33
AVG Volume (30 Days)
13.8K
1.1M
Earning Date
04-28-2026
05-12-2026
Dividend Yield
3.46%
N/A
EPS Growth
14.37
N/A
EPS
17.91
N/A
Revenue
$145,201,729.00
$14,556,000.00
Revenue This Year
N/A
$109.40
Revenue Next Year
N/A
N/A
P/E Ratio
$9.67
N/A
Revenue Growth
6.69
53.24
52 Week Low
$114.11
$0.40
52 Week High
$173.70
$2.09

Technical Indicators

Market Signals
Indicator
DHIL
LCTX
Relative Strength Index (RSI) 70.34 56.12
Support Level $171.71 $1.66
Resistance Level N/A $1.84
Average True Range (ATR) 0.65 0.08
MACD 0.16 0.03
Stochastic Oscillator 98.87 71.67

Price Performance

Historical Comparison
DHIL
LCTX

About DHIL Diamond Hill Investment Group Inc.

Diamond Hill Investment Group Inc sponsors, markets, and provides investment advisory and related services to various U.S. and foreign clients including mutual funds, separate accounts, and private investment funds. The company's objective is to fulfill a fiduciary duty to clients and secondary objectives to achieve an adequate long-term return for shareholders. The company generates its revenue from Investment advisory and fund administration fees.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.

Share on Social Networks: